Brought to you by 
FOPO lands $268.4mm for Synageva
08 Jan 2015
Executive Summary
Synageva BioPharma Corp. (orphan disease therapies) netted $268.4mm through the follow-on sale of 3mm common shares at $94.19. Some of the funds will help support the worldwide launch of Kanuma (sebelipase alfa) for lysosomal acid lipase (LAL) deficiency, begin a Phase I/II trial of its enzyme replacement therapy SBC103, and move preclinical SBC105 for rare disorders of calcification into the human studies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FOPO lands $268.4mm for Synageva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice